Valvular heart disease stems from structural or functional valve abnormalities-most frequently caused by rheumatic complications, degenerative aging processes, infective endocarditis, or traumatic injury-resulting in hemodynamic compromise, which can lead to heart failure or death. Artificial valve replacement restores near-normal cardiac geometry and hemodynamics, promptly relieving symptoms and improving long-term prognosis, though long-term tissue valve deterioration remains a challenge. Perioperative risks escalate significantly with advanced age, comorbidities, and complex reoperations in cases of structural valve deterioration (SVD). Consequently, transcatheter valve-in-valve (ViV) techniques provide a less invasive option for implanting transcatheter heart valves within failed bioprostheses. This document details the first concurrent aortic and mitral ViV procedure using the proprietary ScienCrown valve (Lepu Medtech Inc., Beijing, China). Its unique self-expanding, low-profile design and full retrievability confer exceptional anchoring stability and positional accuracy during deployment, offering crucial technical support for ViV applications in complex anatomical settings. This report substantiates the safe and reproducible use of concurrent dual ViV therapy for bioprosthetic failure, capitalizing on the ScienCrown valve's self-expanding low-frame profile and full retrievability.